DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Phase II Randomized Study of Early Surgery Vs Multiple Sequential Antiepileptic Drug Therapy for Infantile Spasms Refractory to Standard Treatment

Information source: Office of Rare Diseases (ORD)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Spasms, Infantile; Epilepsy

Intervention: carbamazepine (Drug); corticotropin (Drug); nitrazepam (Drug); pyridoxine (Drug); valproic acid (Drug); Surgery (Procedure)

Phase: Phase 2

Status: Completed

Sponsored by: National Center for Research Resources (NCRR)

Official(s) and/or principal investigator(s):
W. Donald Shields, Study Chair, Affiliation: University of California, Los Angeles

Summary

OBJECTIVES: I. Evaluate the efficacy of surgical resection of an identifiable zone of cortical abnormality versus multiple drug therapy in children with infantile spasms refractory to standard therapy.

II. Assess how infantile spasms interfere with development and whether this is partially reversible.

III. Determine the predictors of good surgical outcome and whether surgery permanently controls seizures and improves development.

Clinical Details

Study design: Treatment, Randomized

Detailed description: PROTOCOL OUTLINE: This is a randomized study. Patients are randomly assigned to 1 of 2 treatment groups. The first group undergoes sequential antiepileptic therapy with pyridoxine, corticotropin, valproic acid, carbamazepine, and nitrazepam. The sequence of administration may be altered based on drugs taken prior to entry. Any drug may be omitted due to medical contraindications or prior use at study doses or higher.

The second group undergoes surgical resection of the zone of cortical abnormality. A functional hemispherectomy is performed for hemiparesis or diffuse unihemispheric dysfunction.

If seizures are controlled in the first group at 3 months, the current medication is maintained; if seizures are not controlled, sequential therapy continues to completion. Patients experiencing uncontrolled seizures at 6 months cross to surgery.

Surgical patients experiencing uncontrolled seizures at 3 months or persistent seizures after taper of pre-study antiepileptics cross to drug therapy.

All patients are followed at 6 months and 1, 2, 3, 5, 7, and 10 years.

Eligibility

Minimum age: N/A. Maximum age: 2 Years. Gender(s): Both.

Criteria:

PROTOCOL ENTRY CRITERIA:

Disease Characteristics

- Infantile spasms or seizures with diagnosis based on the following: short muscular

contractions leading to flexion or extension; Single or repetitive electroencephalogram (EEG) consistent with diagnosis, i. e., hypsarrhythmia, modified hypsarrhythmia, multifocal spike and wave abnormalities; developmental quotient less than 70

- Zone of cortical abnormality in 1 lobe, contiguous multilobes, or 1 hemisphere;

confirmed by historical, neurological, and physical evidence, including EEG, closed circuit televised EEG, computed tomography, magnetic resonance imaging, and/or positron-emission tomography; at least 2 abnormal test/imaging results required

- No treatable seizure etiology such as metabolic disease or infection

Prior/Concurrent Therapy

- Failed standard therapy, i. e., refractory to corticotropin (at least 40 IU/day for 14

days) as follows: persistent infantile spasms OR recurrent spasms after discontinuation or taper OR complications requiring dose modification

- At least 1 month of standard antiepileptic drug with documented therapeutic blood

levels

Patient Characteristics

- No medical contraindication to surgery

- English-speaking family

Locations and Contacts

Additional Information

Starting date: November 1993
Last updated: June 23, 2005

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009